MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...

The weight loss drug Wegovy is now available as a tablet in more than 70,000 U.S. pharmacies as well as select telehealth ...

In Canada, the patent for some semaglutide drugs has expired, paving the way for the country to become the first to offer ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight loss in a real-world setting because patients discontinue treatment or use ...

People taking weight-loss drugs are likely to regain the weight they have lost within two years of stopping the medications, ...

Novo Nordisk has launched its first oral GLP-1 weight-loss pill in the United States, expanding beyond injectable treatments ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

The launch of an oral semaglutide pill approved for weight loss represents a new frontier for GLP-1 drugs. Katie Rosseinsky ...

The new oral drug costs as little as $149 a month out of pocket and is expected to broaden access as demand for GLP-1 ...

Health system pharmacists and clinicians are monitoring a wave of drug approvals expected throughout 2026, including first-in-class therapies and expanded uses of existing drugs with implications for ...

Please provide your email address to receive an email when new articles are posted on . Fewer than 2% of patients who received long-acting injectable antipsychotics were readmitted vs. 8.3% of those ...

Drug shortage relief targeted as PAI Pharma acquires Nivagen to expand domestic sterile injectable production in Sacramento, Calif.